LT2999714T - Surišančios molekulės, kurios suriša žmogaus komplemento faktorių c2 ir jų panaudojimas - Google Patents

Surišančios molekulės, kurios suriša žmogaus komplemento faktorių c2 ir jų panaudojimas

Info

Publication number
LT2999714T
LT2999714T LTEP14729463.1T LT14729463T LT2999714T LT 2999714 T LT2999714 T LT 2999714T LT 14729463 T LT14729463 T LT 14729463T LT 2999714 T LT2999714 T LT 2999714T
Authority
LT
Lithuania
Prior art keywords
binding molecules
complement factor
human complement
bind human
bind
Prior art date
Application number
LTEP14729463.1T
Other languages
English (en)
Lithuanian (lt)
Inventor
Cornelis Erik Hack
Cafer YILDIZ
Louis Boon
Petrus Johannes Simons
Original Assignee
Broteio Pharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broteio Pharma B.V. filed Critical Broteio Pharma B.V.
Publication of LT2999714T publication Critical patent/LT2999714T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP14729463.1T 2013-05-23 2014-05-22 Surišančios molekulės, kurios suriša žmogaus komplemento faktorių c2 ir jų panaudojimas LT2999714T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13168941 2013-05-23
PCT/NL2014/050327 WO2014189378A1 (en) 2013-05-23 2014-05-22 Binding molecules that bind human complement factor c2 and uses thereof

Publications (1)

Publication Number Publication Date
LT2999714T true LT2999714T (lt) 2020-07-10

Family

ID=48485015

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP14729463.1T LT2999714T (lt) 2013-05-23 2014-05-22 Surišančios molekulės, kurios suriša žmogaus komplemento faktorių c2 ir jų panaudojimas
LTEP20165165.0T LT3725803T (lt) 2013-05-23 2014-05-22 Surišančios molekulės, kurios suriša žmogaus komplemento faktorių c2b, ir jų panaudojimas

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP20165165.0T LT3725803T (lt) 2013-05-23 2014-05-22 Surišančios molekulės, kurios suriša žmogaus komplemento faktorių c2b, ir jų panaudojimas

Country Status (14)

Country Link
US (2) US9944717B2 (enExample)
EP (2) EP3725803B1 (enExample)
JP (3) JP2016520313A (enExample)
CN (1) CN105492461B (enExample)
AU (1) AU2014269193C1 (enExample)
CA (1) CA2913318C (enExample)
DK (2) DK3725803T3 (enExample)
ES (2) ES2904709T3 (enExample)
HU (2) HUE049769T2 (enExample)
LT (2) LT2999714T (enExample)
MX (1) MX366046B (enExample)
PL (2) PL2999714T3 (enExample)
PT (2) PT3725803T (enExample)
WO (1) WO2014189378A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2914291T3 (pl) 2012-11-02 2022-10-03 Bioverativ Usa Inc. Przeciwciała anty-C1s dopełniacza i ich zastosowania
US9944717B2 (en) * 2013-05-23 2018-04-17 Broteio Pharma B.V. Binding molecules that bind human complement factor C2 and uses thereof
EP4652926A3 (en) 2016-10-12 2026-03-18 Bioverativ USA Inc. Anti-c1s antibodies and methods of use thereof
LT3893924T (lt) 2018-12-13 2024-10-10 argenx BV Antikūnai žmogaus komplemento faktoriui c2b ir jų panaudojimo būdai
GB2584105B (en) 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
AU2020330307A1 (en) * 2019-08-12 2022-03-17 CSL Innovation Pty Ltd Complement C2 binding proteins and uses thereof
EP4469475A1 (en) * 2022-01-29 2024-12-04 Kira Pharmaceuticals (Suzhou) Ltd. Anti-c2 antibodies and uses thereof
GB202407051D0 (en) 2024-05-17 2024-07-03 argenx BV Methods of treating osteoarthritis pain
WO2025257157A1 (en) 2024-06-10 2025-12-18 argenx BV Treatment or prevention of ischemia reperfusion injury in organ tranplantation
WO2025260123A1 (en) * 2024-06-17 2025-12-26 CSL Innovation Pty Ltd Anti-c2 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
PT1265929E (pt) 2000-03-23 2009-10-15 Genentech Inc Inibidores anti-c2/c2a de activação complementar
US9944717B2 (en) 2013-05-23 2018-04-17 Broteio Pharma B.V. Binding molecules that bind human complement factor C2 and uses thereof

Also Published As

Publication number Publication date
PT2999714T (pt) 2020-04-30
HK1223385A1 (zh) 2017-07-28
EP3725803A1 (en) 2020-10-21
ES2784616T3 (es) 2020-09-29
US10717785B2 (en) 2020-07-21
PL2999714T3 (pl) 2020-10-19
LT3725803T (lt) 2022-03-10
US20180319895A1 (en) 2018-11-08
AU2014269193C1 (en) 2020-02-20
HUE057858T2 (hu) 2022-06-28
CA2913318C (en) 2024-03-26
MX366046B (es) 2019-06-26
JP2016520313A (ja) 2016-07-14
AU2014269193B2 (en) 2019-08-15
DK3725803T3 (da) 2022-03-07
JP2020007318A (ja) 2020-01-16
CN105492461B (zh) 2019-11-26
HUE049769T2 (hu) 2020-10-28
AU2014269193A1 (en) 2015-12-17
PT3725803T (pt) 2021-12-24
MX2015016120A (es) 2016-10-28
ES2904709T3 (es) 2022-04-05
WO2014189378A1 (en) 2014-11-27
CA2913318A1 (en) 2014-11-27
CN105492461A (zh) 2016-04-13
EP2999714B1 (en) 2020-04-01
DK2999714T3 (da) 2020-06-02
JP7163254B2 (ja) 2022-10-31
US20160108134A1 (en) 2016-04-21
EP3725803B1 (en) 2021-12-15
JP7414929B2 (ja) 2024-01-16
PL3725803T3 (pl) 2022-04-04
JP2023002684A (ja) 2023-01-10
EP2999714A1 (en) 2016-03-30
US9944717B2 (en) 2018-04-17

Similar Documents

Publication Publication Date Title
ZA201505209B (en) Binding molecules for bcma and cd3
IL254223A (en) CD20 binding compounds and their uses
IL240045A0 (en) Antigen-binding molecules activate bi-specific t cells
IL240838A0 (en) Anti-3–lag binding proteins
PT2999714T (pt) Moléculas de ligação que se ligam ao fator c2 do complemento humano e suas utilizações
SG11201505762XA (en) Il-11r binding proteins and uses thereof
SG11201509260RA (en) Chimeric fvii-xten molecules and uses thereof
SG11201600275PA (en) Novel adsorbent composition and use thereof
LT3077467T (lt) Džioviklio kompozicija ir jos panaudojimas
ZA201506186B (en) Ligand binding molecules and uses thereof
SI3072905T1 (sl) IL-17A-vezavno sredstvo in uporabe le-tega
ZA201507808B (en) Binding element
GB201314610D0 (en) Compounds and their uses
GB201306588D0 (en) Peptides and Binding Partners Therefor
ZA201503962B (en) Fines binding process and binding composition thereof
HU4488U (en) Plaster-coated and edge-protected chipboard
GB201314294D0 (en) Binding surfaces